glua2

TAT-GluA2 3Y acetate is an inhibitor of AMPA receptor endocytosis.Systemic administration of Tat-GluA2(3Y) during the induction phase of d-amphetamine blocked maintenance of behavioural sensitization and attenuated the maintenance of neurochemical sensitization of rat.

CMPDA is a positive allosteric modulator of AMPA receptors [EC50s: 45.4 nM/63.4 nM for GluA2i/GluA2o receptor].

BDZ-P7 inhibits AMPA receptors GluA2, GluA1/2, GluA2/3, and GluA1 subunits with IC50 values of 3.03 μM, 3.14 μM, 3.19 μM, and 3.2 μM, respectively. It exhibits neuroprotective effects and is capable of restoring motor functions in mouse models of Parkinson’s disease.

p3Ysh-3, a peptide inhibitor targeting the STEP Phosphatase-GluA2 AMPA receptor interaction, exhibits a Ki of 1.09 μM. It effectively reverses memory deficits and demonstrates anxiolytic and antidepressant effects in scopolamine-treated rat models, positioning itself as a promising lead compound for the development of novel cognitive enhancers and behavioral modulators [1].

p-fin4 is a peptide inhibitor targeting the interaction between STEP Phosphatase and GluA2 AMPA receptor, exhibiting a Ki of 0.4 μM. This compound has been shown to reverse memory deficits and exert anxiolytic and antidepressant effects in scopolamine-treated rats, suggesting its potential as a lead compound for developing novel cognitive enhancers and behavioral modulators [1].

pep2-AVKI is an inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).

pep2-AVKI acetate(1315378-69-8 free base) An inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to proteins that interact with C-kinase (PICK1). Does not affect GluA2 binding to GRIP or ABP, nor does it increase AMPA current amplitude or affect long-term depression (LTD).

pep2-EVKI is an inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).

Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and

Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces pos

Pep2m, myristoylated acetate is a Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates A